This expert commentary examines key phase III clinical trial data presented at the 2026 ASCO Annual Meeting across pancreatic biliary tract hepatocellular gastroesophageal and colorectal cancers Faculty discuss the efficacy safety biomarker and patientreported outcome findings from RASolute302 FIGHT302 EMERALD3 HERIZONGEA01 and HORIZONCRC01 with particular attention to emerging RAS FGFR2 and HER2directed therapies and the integration of immunotherapy with liverdirected treatment The commentary also addresses trial limitations treatment sequencing toxicity and the extent to which these findings may alter current standards of care helping learners determine where new evidence is practice changing and where additional followup or validation is still needed
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 12001 Sunrise Valley Drive
Pricing
98% of listed courses are free
294 of a sample of 300 are free · 534 courses listed here.
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Clinical Informatics
- Clinician Wellness & Burnout
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Geriatric Psychiatry
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Laryngology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Infectious Diseases
- Pediatric Otolaryngology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Recorded-from-live session
- Credit · Up to 0.25 credits
- MOC · Up to 0.25 points
- Commercial Support
-
ReleasedJul 30, 2026
-
Last day to claim creditJan 30, 2027 4 months left
-
Physicians’ Education Resource From Data to Decisions: Applying the Latest Evidence for New Targeted Therapies in HER2-Positive Gastroesophageal Adenocarcinoma
-
American Society of Clinical Oncology Gastrointestinal Cancer Gastroesophageal, Pancreatic, and Hepatobiliary (Rapid Oral Abstract Session) – 2026 ASCO Annual Meeting
-
touchIME +1 HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
-
Clinical Care Options, LLC (dba Decera Clinical Education) The HER2 Horizon: The Next Era of HER2 Targeted Treatment in GI Cancer
-
Clinical Care Options, LLC (dba Decera Clinical Education) Lung Cancer Highlights From ASCO 2026: Expert Perspectives on Emerging Practice-Changing Data
-
Clinical Care Options, LLC (dba Decera Clinical Education) Key Studies in Breast Cancer: Independent Conference Coverage of the 2026 ASCO Annual Meeting
